Amide Analogues of Trichostatin A as Inhibitors of Histone Deacetylase and Inducers of Terminal Cell Differentiation
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Inhibitors of histone deacetylase (HD) bear great potential as new drugs due to their ability to modulate transcription and to induce apoptosis or differentiation in cancer cells. We have described previously analogues of the complex natural HD inhibitors trapoxin B and trichostatin A with activities in the submicromolar range. Here we report structure-activity relationship analyses of further analogues of trichostatin A with respect to in vitro inhibition of maize HD-2 and their ability to induce terminal cell differentiation in Friend leukemic cells. This is the first report that shows the correlation between HD inhibitory activity and action on cancer cells on a larger series of similar compounds. Only the compounds that inhibit HD induce differentiation and/or exert antiproliferative activities in cell culture. Our studies support the use of in vitro systems as screening tools and provide structure-activity relationships that merit further investigation of this interesting target.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These inhibitors are active against class I and class II HDACs, and have the ability to induce multiple effects within cells, including cell differentiation, induction of cell cycle arrest, and suppression of tumor growth (Jung et al., 1999; Almenara et al., 2002; Richon et al., 1998; Yoshida et al., 1990a, 1990b).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Jung et al., 1999
Citations
Cites
Cell Biology: a Laboratory Handbook
Harris, A. (1995) · Journal of Medical Genetics · doi:10.1136/jmg.32.9.759 · Cited by 1,225
Grignani, F., De Matteis, S., Nervi, C., Tomassoni, L., Gelmetti, V., Cioce, M., Fanelli, M., Ruthardt, M., Ferrara, F. F., Zamir, I., et al. (1998) · Nature · doi:10.1038/35901 · Cited by 1,004
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914
Borrow, J., Stanton, V. P., Andresen, J. M., Becher, R., Behm, F. G., Chaganti, R. S. K., Civin, C. I., Disteche, C., Dubé, I., Frischauf, A. M., et al. (1996) · Nature Genetics · doi:10.1038/ng0996-33 · Cited by 771
Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., & Nakanishi, O. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4592 · Cited by 694
Cellular Differentiation Regulated by Gibberellin in the Arabidopsis thaliana pickle Mutant
Ogas, J., Cheng, J.-C., Sung, Z. R., & Somerville, C. (1997) · Science · doi:10.1126/science.277.5322.91 · Cited by 344
Histones of Drosophila Embryos
Alfageme, C. R., Zweidler, A., Mahowald, A., & Cohen, L. H. (1974) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)42534-9 · Cited by 336
Synthesis and Histone Deacetylase Inhibitory Activity of New Benzamide Derivatives
Suzuki, T., Ando, T., Tsuchiya, K., Fukazawa, N., Saito, A., Mariko, Y., Yamashita, T., & Nakanishi, O. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980565u · Cited by 293
Identification of Maize Histone Deacetylase HD2 as an Acidic Nucleolar Phosphoprotein
Lusser, A., Brosch, G., Loidl, A., Haas, H., & Loidl, P. (1997) · Science · doi:10.1126/science.277.5322.88 · Cited by 232
Self-citationHistone acetylation: facts and questions
Loidl, P. (1994) · Chromosoma · doi:10.1007/bf00337382 · Cited by 171
Self-citation
Research works printed but not linked: 11
- Pennisi E, 1997, Science, 275, 157
- Pazin M. J., 1997, Cell, 86, 328
- Liu R. J., 1998, Nature, 391, 814
- Jung M., 1997, Bioorg. Med. Chem. Lett., 7, 1658
- Yoshida M., 1990, J. Biol. Chem, 265, 17179
- He L. Z., 1998, Nature Genet., 18, 135
- Lea M. A., 1995, Anticancer Res., 15, 884
- Warrell, 1999, J. Natl. Cancer Inst., 90, 1625
- Hagmann W. K., 1996, Annu. Rep. Med. Chem., 31, 240
- Richon V. M., 1999, 90th Annual Meeting of the AACR, Apr 10−14
- Schmidt K., 1999, Inhibitors of histone deacetylase suppress the growth of MCF-7 breast cancer cells. Arch. Pharm. Pharm. Med. Chem
Cited by
Impact of Natural Products on Developing New Anti-Cancer Agents
Cragg, G. M., Grothaus, P. G., & Newman, D. J. (2009) · Chemical Reviews · doi:10.1021/cr900019j · Cited by 1,302
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
Cheng, Y., He, C., Wang, M., Ma, X., Mo, F., Yang, S., Han, J., & Wei, X. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0095-0 · Cited by 1,097
Chang, F., Steelman, L. S., Lee, J. T., Shelton, J. G., Navolanic, P. M., Blalock, W. L., Franklin, R. A., & McCubrey, J. A. (2003) · Leukemia · doi:10.1038/sj.leu.2402945 · Cited by 725
Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases
Somoza, J. R., Skene, R. J., Katz, B. A., Mol, C., Ho, J. D., Jennings, A. J., Luong, C., Arvai, A., Buggy, J. J., Chi, E., et al. (2004) · Structure · doi:10.1016/j.str.2004.04.012 · Cited by 710
“…San Diego, California 92121. multiple effects within cells, including cell differentiation, induction of cell cycle arrest, and suppression of tumor and encompass the residues that form the enzyme’s growth (Jung et al., 1999; Almenara et al., 2002; Richon active site and catalytic machinery.”
BackgroundGrozinger, C. M., & Schreiber, S. L. (2002) · Chemistry & Biology · doi:10.1016/s1074-5521(02)00092-3 · Cited by 537
Generation of Hepatocyte-Like Cells from Human Embryonic Stem Cells
Rambhatla, L., Chiu, C.-P., Kundu, P., Peng, Y., & Carpenter, M. K. (2003) · Cell Transplantation · doi:10.3727/000000003783985179 · Cited by 437
Histone deacetylase inhibitors
Monneret, C. (2005) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2004.10.001 · Cited by 338
Histone deacetylation in epigenetics: An attractive target for anticancer therapy
Mai, A., Massa, S., Rotili, D., Cerbara, I., Valente, S., Pezzi, R., Simeoni, S., & Ragno, R. (2005) · Medicinal Research Reviews · doi:10.1002/med.20024 · Cited by 319
Epigenetics—An Epicenter of Gene Regulation: Histones and Histone‐Modifying Enzymes
Biel, M., Wascholowski, V., & Giannis, A. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200461346 · Cited by 316
A Fluorogenic Histone Deacetylase Assay Well Suited for High-Throughput Activity Screening
Wegener, D., Wirsching, F., Riester, D., & Schwienhorst, A. (2003) · Chemistry & Biology · doi:10.1016/s1074-5521(02)00305-8 · Cited by 282
Histone Deacetylase 1 Phosphorylation Promotes Enzymatic Activity and Complex Formation
Pflum, M. K. H., Tong, J. K., Lane, W. S., & Schreiber, S. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105590200 · Cited by 256
Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review
Acharya, M. R., Sparreboom, A., Venitz, J., & Figg, W. D. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.014167 · Cited by 235
“It was developed as an antifungal agent but is relatively unstable; its toxicity to patients and lack of specificity for certain HDACs motivated the search for other substances (Jung et al., 1999; Jung, 2001).”
BackgroundHistone deacetylase inhibitors as therapeutics for polyglutamine disorders
Butler, R., & Bates, G. P. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1989 · Cited by 214
Devgan, V., Mammucari, C., Millar, S. E., Brisken, C., & Dotto, G. P. (2005) · Genes & Development · doi:10.1101/gad.341405 · Cited by 209
“Trichostatin A [Jung et al. 1999]) plus/minus an”
BackgroundMarek, M., Kannan, S., Hauser, A.-T., Moraes Mourão, M., Caby, S., Cura, V., Stolfa, D. A., Schmidtkunz, K., Lancelot, J., Andrade, L., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003645 · Cited by 173
“Towards this goal, we first determined the structures of smHDAC8 in complex with two generic HDAC inhibitors, SAHA (N-hydroxy-N9-phenyloctanediamide; [44]) and M344 (N-hydroxy-7-(4-dimethylaminobenzoyl)-aminoheptanamide; [45]), either by co-crystallization or by soaking.”
MethodSelf-citationShankar, S., & Srivastava, R. K. (2008) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4020-6554-5_13 · Cited by 160
Mechanisms involved in the induced differentiation of leukemia cells
Tsiftsoglou, A. S., Pappas, I. S., & Vizirianakis, I. S. (2003) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.09.002 · Cited by 181
Hahnen, E., Eyüpoglu, I. Y., Brichta, L., Haastert, K., Tränkle, C., Siebzehnrübl, F. A., Riessland, M., Hölker, I., Claus, P., Romstöck, J., et al. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03868.x · Cited by 150
“1996), as well as the benzamides N-(2Aminophenyl)-4-[N-(pyridine-3-ylmethoxycarbonyl)aminomethyl]benzamide (MS-275) and 4-Dimethylamino-N-(6hydroxycarbamoylhexyl)benzamide N-Hydroxy-7-(4-dimethylaminobenzoyl)aminoheptanamide (M344) (Jung et al. 1999; Saito et al. 1999) for SMA treatment.”
BackgroundTrifluoromethyl ketones as inhibitors of histone deacetylase
Frey, R. R., Wada, C. K., Garland, R. B., Curtin, M. L., Michaelides, M. R., Li, J., Pease, L. J., Glaser, K. B., Marcotte, P. A., Bouska, J. J., et al. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00754-0 · Cited by 165
An Easy and Convenient Synthesis of Weinreb Amides and Hydroxamates
Luca, L. D., Giacomelli, G., & Taddei, M. (2001) · The Journal of Organic Chemistry · doi:10.1021/jo015524b · Cited by 134
Targeting Histone Deacetylases in Diseases: Where Are We?
Benedetti, R., Conte, M., & Altucci, L. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5776 · Cited by 126
“HDACi derive from natural or synthetic sources and can be classified into five main groups (16): (i) Hydroxamates, including trichostatin A (TSA), suberoylanilide hydroxamic acid (also called Vorinostat), LAQ824, LBH589 (Panabinostat), or PXD101 (Belinostat), M344, CR2408, abexinostat hydrochloride (PCI-24781) (ii) al…”
BackgroundInfluentialRießland, M., Brichta, L., Hahnen, E., & Wirth, B. (2006) · Human Genetics · doi:10.1007/s00439-006-0186-1 · Cited by 126
“Here, we report on the novel drug M344, which belongs to the benzamide class of HDAC inhibitors ( Jung et al. 1999 ) and has a highly significant impact on SMN2 transcript and protein levels at low doses.”
BackgroundSubtype Selective Substrates for Histone Deacetylases
Heltweg, B., Dequiedt, F., Marshall, B. L., Brauch, C., Yoshida, M., Nishino, N., Verdin, E., & Jung, M. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0497592 · Cited by 126
Self-citationStrategies To Design Selective Histone Deacetylase Inhibitors
Melesina, J., Simoben, C. V., Praetorius, L., Bülbül, E. F., Robaa, D., & Sippl, W. (2021) · ChemMedChem · doi:10.1002/cmdc.202000934 · Cited by 118
Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC)
Curtin, M. L., Garland, R. B., Heyman, H. R., Frey, R. R., Michaelides, M. R., Li, J., Pease, L. J., Glaser, K. B., Marcotte, P. A., & Davidsen, S. K. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00622-4 · Cited by 121
Improved fluorogenic histone deacetylase assay for high-throughput-screening applications
Wegener, D., Hildmann, C., Riester, D., & Schwienhorst, A. (2003) · Analytical Biochemistry · doi:10.1016/s0003-2697(03)00426-3 · Cited by 111
Konsoula, R., & Jung, M. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.05.001 · Cited by 108
“The thiol functionality has been shown to be a good replacement for hydroxamic acid, since zinc ion is highly thiophilic and thiol derivatives have been documented to inhibit zinc dependent enzymes including matrix metalloproteinases and angiotensin converting enzyme (Jung et al., 1999; Michaelides et al., 2001; Pikul…”
BackgroundSelf-citationNakao, Y., Yoshida, S., Matsunaga, S., Shindoh, N., Terada, Y., Nagai, K., Yamashita, J. K., Ganesan, A., van Soest, R. W. M., & Fusetani, N. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200602047 · Cited by 109
Tang, H., Wang, X. S., Huang, X., Roth, B. L., Butler, K. V., Kozikowski, A. P., Jung, M., & Tropsha, A. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci800366f · Cited by 109
Self-citationThiol-based SAHA analogues as potent histone deacetylase inhibitors
Suzuki, T., Kouketsu, A., Matsuura, A., Kohara, A., Ninomiya, S.-I., Kohda, K., & Miyata, N. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.03.063 · Cited by 103
Endogenous Inhibition of Histone Deacetylase 1 by Tumor-Suppressive Maspin
Li, X., Yin, S., Meng, Y., Sakr, W., & Sheng, S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1578 · Cited by 97
“© 2006 American Association for Cancercancerres.aacrjournals.org Downloaded from have shown that HDAC1 may be inhibited by synthetic compounds [e.g., SAHA (27) and M344 (28)] or metabolic by-products (e.g., 9-HSA; ref.”
BackgroundInfluentialEnzyme Inhibitors from Marine Invertebrates
Nakao, Y., & Fusetani, N. (2007) · Journal of Natural Products · doi:10.1021/np060600x · Cited by 89
Pontiki, E. A., & Hadjipavlou‐Litina, D. (2011) · Medicinal Research Reviews · doi:10.1002/med.20200 · Cited by 91
Induction of human γ globin gene expression by histone deacetylase inhibitors
Cao, H., Stamatoyannopoulos, G., & Jung, M. (2004) · Blood · doi:10.1182/blood-2003-02-0478 · Cited by 86
Self-citationFournel, M., Trachy-Bourget, M.-C., Yan, P. T., Kalita, A., Bonfils, C., Beaulieu, C., Fréchette, S., Leit, S. M., Abou-Khalil, E., Woo, S.-H., et al. (2002) · PubMed · Cited by 94
Dowling, D. P., Gattis, S. G., Fierke, C. A., & Christianson, D. W. (2010) · Biochemistry · doi:10.1021/bi1005046 · Cited by 81
“benzamide (designated “M344” (23, 39)) were prepared to obtain”
Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases
Hildmann, C., Wegener, D., Riester, D., Hempel, R., Schober, A., Merana, J., Giurato, L., Guccione, S., Nielsen, T. K., Ficner, R., et al. (2006) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2006.01.030 · Cited by 77
Li, Y., Sang, S., Ren, W., Pei, Y., Bian, Y., Chen, Y., & Sun, H. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113874 · Cited by 77
Stolfa, D. A., Marek, M., Lancelot, J., Hauser, A.-T., Walter, A., Leproult, E., Melesina, J., Rumpf, T., Wurtz, J.-M., Cavarelli, J., et al. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.03.007 · Cited by 75
“As congeners of M344, we included a benzoic acid derivative (3) [18] and its 1,4-cyclohexylene analogue (4) [29].”
BackgroundSelf-citationMassa, S., Mai, A., Sbardella, G., Esposito, M., Ragno, R., Loidl, P., & Brosch, G. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm015515v · Cited by 77
Self-citationSchäfer, S., Saunders, L. R., Eliseeva, E. D., Velena, A., Jung, M., Schwienhorst, A., Strasser, A., Dickmanns, A., Ficner, R., Schlimme, S., et al. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.10.092 · Cited by 80
Self-citationPharmacoinformatic Investigation of Medicinal Plants from East Africa
Simoben, C. V., Qaseem, A., Moumbock, A. F. A., Telukunta, K. K., Günther, S., Sippl, W., & Ntie‐Kang, F. (2020) · Molecular Informatics · doi:10.1002/minf.202000163 · Cited by 75
Wittich, S., Scherf, H. R., Xie, C., Brosch, G., Loidl, P., Gerhäuser, C., & Jung, M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0208119 · Cited by 72
Self-citationDesign and synthesis of a novel class of histone deacetylase inhibitors
Lavoie, R., Bouchain, G., Fréchette, S., Woo, S. H., Khalil, E. A., Leit, S. M., Fournel, M., Yan, P. T., Trachy-Bourget, M.-C., Beaulieu, C., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00552-2 · Cited by 70
Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention
Ružić, D., Djoković, N., Srdić‐Rajić, T., Echeverría, C., Nikolic, K. M., & Santibanez, J. F. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010209 · Cited by 71
“Furthermore, the cap is usually built from a heterocyclic or carbocyclic group that interacts with the aromatic amino acid residues located either close to the outer domain of the active site or at the external surface of the enzyme [64,66].”
BackgroundIdentification, Synthesis, and Enzymology of Non‐natural Glucosinolate Chemopreventive Candidates
Mays, J. R., Weller, R. L., Sarfaraz, S., Mukhtar, H., & Rajski, S. R. (2008) · ChemBioChem · doi:10.1002/cbic.200700586 · Cited by 72
Kraker, A. J., Mizzen, C. A., Hartl, B. G., Miin, J., Allis, C. D., & Merriman, R. L. (2003) · PubMed · Cited by 64
Volmar, C.-H., Salah-Uddin, H., Janczura, K. J., Halley, P., Lambert, G., Wodrich, A., Manoah, S., Patel, N. H., Sartor, G. C., Mehta, N., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707544114 · Cited by 64
Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling
Chen, Y., Jiang, Y., Zhou, J., Yu, Q., & You, Q. (2007) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2007.10.007 · Cited by 61
Papeleu, P., Vanhaecke, T., Elaut, G., Vinken, M., Henkens, T., Snykers, S., & Rogiers, V. (2005) · Critical Reviews in Toxicology · doi:10.1080/10408440590935639 · Cited by 64
Yang, Y., Balch, C., Kulp, S. K., Mand, M. R., Nephew, K. P., & Chen, C. (2009) · Neoplasia · doi:10.1593/neo.09204 · Cited by 61
“[15] Jung M, Brosch G, Kolle D, Scherf H, Gerhauser C, and Loidl P (1999).”
Background3D-QSAR of histone deacetylase inhibitors: hydroxamate analogues
Juvale, D. C., Kulkarni, V. V., Deokar, H. S., Wagh, N. K., Padhyé, S., & Kulkarni, V. M. (2006) · Organic & Biomolecular Chemistry · doi:10.1039/b606365a · Cited by 55
Mai, A., Massa, S., Ragno, R., Esposito, M., Sbardella, G., Nocca, G., Scatena, R., Jesacher, F., Loidl, P., & Brosch, G. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm011088+ · Cited by 61
Self-citationPark, J., Jong, H.-S., Kim, S. G., Jung, Y., Lee, K., Lee, J., Kim, D., Bang, Y., & Kim, T. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0260-8 · Cited by 55
“Several reports have proposed a generalized HDI structure as specificity element (cap structure) spacer (linker)-Zn ligand (functional moiety) [18, 19].”
BackgroundHeterocyclic ketones as inhibitors of histone deacetylase
Vasudevan, A., Ji, Z., Frey, R. R., Wada, C. K., Steinman, D. H., Heyman, H. R., Guo, Y. P., Curtin, M. L., Guo, J., Li, J., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.09.007 · Cited by 56
Bieliauskas, A. V., Weerasinghe, S. V. W., & Pflum, M. K. H. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.01.117 · Cited by 57
A Microplate Reader-Based Nonisotopic Histone Deacetylase Activity Assay
Heltweg, B., & Jung, M. (2002) · Analytical Biochemistry · doi:10.1006/abio.2001.5542 · Cited by 55
Self-citationBhuiyan, M. P. I., Kato, T., Okauchi, T., Nishino, N., Maeda, S., Nishino, T. G., & Yoshida, M. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.12.063 · Cited by 50
Salmi, C., Fabre, A. J., Dequiedt, F., Restouin, A., Castellano, R., Garbit, S., Roche, P., Morelli, X., Brunel, J. M., & Collette, Y. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901358y · Cited by 55
Energy based pharmacophore mapping of HDAC inhibitors against class I HDAC enzymes
Kalyaanamoorthy, S., & Chen, Y. P. (2012) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2012.08.009 · Cited by 48
Chromatin Modifications as Targets for New Anticancer Drugs
Schäfer, S., & Jung, M. (2005) · Archiv der Pharmazie · doi:10.1002/ardp.200500984 · Cited by 60
Self-citationElaut, G., Török, G., Vinken, M., Laus, G., Papeleu, P., Tourwé, D., & Rogiers, V. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.12.1320 · Cited by 53
“Jung et al. (1999) synthesized different structural analogs of TSA and compared their HDAC-inhibiting activity as well as their ability to induce terminal cell differentiation in Friend leukemic cells.”
BackgroundHistone acetylation: plants and fungi as model systems for the investigation of histone deacetylases
Graessle, S., Loidl, P., & Brosch, G. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000894 · Cited by 57
Self-citationBanno, K., Kisu, I., Yanokura, M., Masuda, K., Ueki, A., Kobayashi, Y., Susumu, N., & Aoki, D. (2012) · Epigenomics · doi:10.2217/epi.12.13 · Cited by 51
Kim, D.-K., Lee, J. Y., Kim, J.-S., Ryu, J.-H., Choi, J.-Y., Lee, J., Im, G.-J., Kim, T.-K., Seo, J. W., Park, H., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030377q · Cited by 48
Abdel-Atty, M. M., Farag, N. A., Kassab, S. E., Serya, R. A. T., & Abouzid, K. A. M. (2014) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2014.08.006 · Cited by 42
Epigenetik – ein Epizentrum der Genregulation: Histone und histonmodifizierende Enzyme
Biel, M., Wascholowski, V., & Giannis, A. (2005) · Angewandte Chemie · doi:10.1002/ange.200461346 · Cited by 47
Zhang, F., Huang, Q., Yan, J., & Chen, Z. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b00400 · Cited by 42
Choubey, S. K., & Jeyakanthan, J. (2016) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2016.09.008 · Cited by 39
Ferreira, R. C., Popova, E. Y., James, J., Briones, M. R. S., Zhang, S. S.-M., & Barnstable, C. J. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.756643 · Cited by 42
“CAS 193551-00-7 is a benzamide derived from entinostat with selective inhibitory activity for HDAC1 in the range of 100 nM (23).”
BackgroundRecent progress in the development of assays suited for histone deacetylase inhibitor screening
Wegener, D., Hildmann, C., & Schwienhorst, A. (2003) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.08.008 · Cited by 45
Identification of type-specific anticancer histone deacetylase inhibitors: road to success
Noureen, N., Rashid, H., & Kalsoom, S. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1324-y · Cited by 43
“In developing potent HDAC inhibitors, this three-component concept has proved to be successful [58].”
BackgroundLü, W., Yao, X., Ouyang, P., Dong, N., Wu, D., Jiang, X., Wu, Z., Zhang, C., Xu, Z., Tang, Y., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01507 · Cited by 44
Meisel, A., Harms, C., Yildirim, F., Bösel, J., Kronenberg, G., Harms, U., Fink, K., & Endres, M. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04016.x · Cited by 41
“The generally accepted Ki value of TSA for general HDACs is about 5–10 nM (Jung et al. 1999; Marks 2004; Monneret 2005).”
BackgroundChlamydocin–hydroxamic acid analogues as histone deacetylase inhibitors
Nishino, N., Jose, B., Shinta, R., Kato, T., Komatsu, Y., & Yoshida, M. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.08.041 · Cited by 39
A Homogeneous Nonisotopic Histone Deacetylase Activity Assay
Heltweg, B., & Jung, M. (2003) · SLAS DISCOVERY · doi:10.1177/1087057102239644 · Cited by 37
“The inhibitors MD85, M360, and M344 were synthesized according to published procedures.(19,20)”
MethodSelf-citationDevelopment of a fluorescence polarization based assay for histone deacetylase ligand discovery
Mazitschek, R., Patel, V., Wirth, D. F., & Clardy, J. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.04.007 · Cited by 41
Klan, N., Seuter, S., Schnur, N., Jung, M., & Steinhilber, D. (2003) · Biological Chemistry · doi:10.1515/bc.2003.086 · Cited by 43
“acetylation in leukemic cells, which correlated with their ability to induce terminal cell differentiaton (Jung et al., 1999).”
BackgroundResultInfluentialSelf-citationLi, X., Kaplun, A., Lonardo, F., Heath, E. I., Sarkar, F. H., Irish, J. C., Sakr, W., & Sheng, S. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0505 · Cited by 37
“Chemicals, Cell Lines and Cell Culture: Pan HDAC inhibitor M344, an analogue of classic HDAC inhibitor trichostatin A (TSA) [25, 26], was purchased from Calbiochem (La Jolla, CA).”
MethodHistone deacetylase inhibitors induce antigen specific anergy in lymphocytes: A comparative study
Edens, R. E., Dagtas, A. S., & Gilbert, K. M. (2006) · International Immunopharmacology · doi:10.1016/j.intimp.2006.07.001 · Cited by 36
Galletti, M., Cantoni, S., Zambelli, F., Valente, S., Palazzini, M., Manes, A., Pasquinelli, G., Mai, A., Galiè, N., & Ventura, C. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.011 · Cited by 30
“To further demonstrate that HDAC1 was the key effector of HDACi on PASMCs migration and proliferation, HDAC1-I, a commercial HDAC1 specific inhibitor [27,28] was utilized.”
BackgroundMethodPreclinical Studies of Chemotherapy Using Histone Deacetylase Inhibitors in Endometrial Cancer
Takai, N., & Narahara, H. (2010) · Obstetrics and Gynecology International · doi:10.1155/2010/923824 · Cited by 38
“demonstrated that M344 is a potent HDACI and an inducer of terminal cell differentiation [44].”
BackgroundAn Overview of HDAC Inhibitors and their Synthetic Routes
Peng, X., Liao, G., Sun, P., Yu, Z., & Chen, J. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190227221507 · Cited by 31
Histone deacetylase inhibitor assay based on fluorescence resonance energy transfer
Riester, D., Hildmann, C., Schwienhorst, A., & Meyer‐Almes, F. (2007) · Analytical Biochemistry · doi:10.1016/j.ab.2006.12.019 · Cited by 29
Wang, H., Lim, Z., Zhou, Y. F., Ng, M., Lu, T., Lee, K. C. L., Sangthongpitag, K., Goh, K. C., Wang, X., Wu, X., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.04.041 · Cited by 31
Meinke, P. T., Colletti, S. L., Ayer, M. B., Darkin‐Rattray, S. J., Myers, R. W., Schmatz, D. M., Wyvratt, M. J., & Fisher, M. H. (2000) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)01364-2 · Cited by 32
Moradei, O. M., Leit, S. M., Zhou, N., Fréchette, S., Paquin, I., Raeppel, S. L., Gaudette, F., Bouchain, G., Woo, S. H., Vaisburg, A., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.05.005 · Cited by 29
Shivashimpi, G. M., Amagai, S., Kato, T., Nishino, N., Maeda, S., Nishino, T. G., & Yoshida, M. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.08.041 · Cited by 29
HDAC as a Therapeutic Target for Treatment of Endometrial Cancers
Ren, J., Zhang, J., Cai, H., Li, Y., Zhang, Y., Zhang, X., Zhao, D., Li, Z., Ma, H., Wang, J., et al. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990528 · Cited by 28
(2-Amino-phenyl)-amides of ω-substituted alkanoic acids as new histone deacetylase inhibitors
Vaisburg, A., Bernstein, N., Fréchette, S., Allan, M., Abou-Khalil, E., Leit, S. M., Moradei, O. M., Bouchain, G., Wang, J., Woo, S. H., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.08.083 · Cited by 28
Nelson, E. R., & Habibi, H. (2008) · Endocrinology · doi:10.1210/en.2008-0107 · Cited by 28
Lee, K., Kim, J. H., Park, J., Kim, H., Song, S., Kim, S. G., Kim, T. Y., Jong, H.-S., Jung, K. H., Im, S., et al. (2006) · PubMed · Cited by 27
Konsoula, Z., Cao, H., Velena, A., & Jung, M. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0629 · Cited by 27
Self-citationNovel chemotherapy using histone deacetylase inhibitors in cervical cancer.
Takai, N., Kira, N., Ishii, T., Nishida, M., Nasu, K., & Narahara, H. (2011) · PubMed · Cited by 29
Amide analogues of TSA: synthesis, binding mode analysis and HDAC inhibition
Ommeslaeghe, K. V., Elaut, G., Brecx, V., Papeleu, P., Iterbeke, K., Geerlings, P., Tourwé, D., & Rogiers, V. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00284-1 · Cited by 33
Elaut, G., Laus, G., Alexandre, E., Richert, L., Bachellier, P., Tourwé, D., Rogiers, V., & Vanhaecke, T. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.116202 · Cited by 26
“Benzamides 1-7 (Table 1) were prepared as described previously by Jung et al. (1997, 1999) by coupling of the benzoic acid to the methyl ester of 5-aminovaleric acid, 6-aminohexanoic acid, and (E)-5-amino-2-pentenoic acid, followed by saponification of the ester, formation of the Obenzyl…”
MethodResultInfluential5,5-Dimethyl-1,4,2-dioxazoles as Versatile Aprotic Hydroxamic Acid Protecting Groups
Couturier, M. A., Tucker, J. L., Proulx, C., Boucher, G., Dubé, P., Andresen, B. M., & Ghosh, A. K. (2002) · The Journal of Organic Chemistry · doi:10.1021/jo0256890 · Cited by 26
Trichostatin a inhibits β‐casein expression in mammary epithelial cells
Pujuguet, P., Radisky, D. C., Levy, D., Lacza, C. T., & Bissell, M. J. (2001) · Journal of Cellular Biochemistry · doi:10.1002/jcb.1260 · Cited by 25
“Pharmacological inhibitors of histone deacetylases are capable of inducing or potentiating the differentiation of tumor cells [Minucci et al., 1997; Marks et al., 2000]; this property is so general that it can be used as a screen to identify novel inhibitors [Jung et al., 1999].”
BackgroundInteraction of aliphatic cap group in inhibition of histone deacetylases by cyclic tetrapeptides
Nishino, N., Shivashimpi, G. M., Soni, P., Bhuiyan, M. P. I., Kato, T., Maeda, S., Nishino, T. G., & Yoshida, M. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.09.021 · Cited by 24
Xiang, H., & Ye, Y. (2023) · ACS Catalysis · doi:10.1021/acscatal.3c04974 · Cited by 24
Metadata
- Authors
- Jung, M., Brosch, G., Kölle, D., Scherf, H., Gerhäuser, C., & Loidl, P.
- Affiliations
- German Cancer Research Center (DE)
- Corresponding author
- Jung, Manfred
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1999-10-15
- Volume
- 42
- Issue
- 22
- Pages
- 4669-4679
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2071513872
- Cited by
- 176
- References
- 18
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 7 · 2022: 4 · 2021: 6 · 2020: 3 · 2019: 2 · 2018: 2 · 2017: 2 · 2016: 4 · 2015: 3 · 2014: 5 · 2013: 6 · 2012: 4
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- histone deacetylase inhibitors, amide derivatives, structure-activity relationship, Friend leukemia cells, antiproliferative activity, anticancer drug discovery
- MeSH terms
- Animals, Cell Differentiation, Enzyme Inhibitors, Histone Deacetylases, Hydroxamic Acids, Models, Molecular, Structure-Activity Relationship, Tumor Cells, Cultured, Mice, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.